Effect of Silibinin(A) as a Potential Anti-obesity Agent

Status Active, not recruiting

Clinical Trial Summary

Our preliminary reports have found in silico and in vitro that the milk thistle derivative Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical anti-obesity drug orlistat. Therefore, the investigators want to carry out the present trial in order to confirm that Silibinin(A) is able to in vivo inhibit pancreatic lipase, which will reduce the fat absorption and therefore will decrease the amount of energy from food intake. Considering that milk thistle has been extensively studied in humans as liver-protector, the investigators consider that the use of human subjects will be of great interest to accelerate the employment of this compound to improve the effectiveness of dietary treatment in overweight/obese subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05069298
Study type	Interventional
Source	Universidad Católica San Antonio de Murcia
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 12, 2023
Completion date	December 21, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04998695` - Health Effects of Consuming Olive Pomace Oil	N/A
Recruiting	`NCT03947866` - Ezetimibe-Rosuvastatin Evaluation Study
Completed	`NCT01709513` - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)	Phase 3
Completed	`NCT01212900` - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression	Phase 4
Completed	`NCT00001154` - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed	`NCT02550288` - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)	Phase 3
Completed	`NCT03929198` - Translation of Pritikin Program to the Community	N/A
Completed	`NCT04485793` - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia	N/A
Completed	`NCT02341924` - Validating the "Foods for Health" Portfolio of Functional Food Products	N/A
Active, not recruiting	`NCT02223793` - Vascular Lifestyle-Intervention and Screening in Pharmacy	N/A
Completed	`NCT01934608` - The Effect of Synching Prescription Refills on Adherence	N/A
Completed	`NCT01941836` - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients	Phase 2
Recruiting	`NCT01705873` - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen	N/A
Completed	`NCT01678521` - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients	N/A
Completed	`NCT01670734` - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects	Phase 1
Completed	`NCT01370590` - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)	Phase 3
Completed	`NCT01370603` - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)	Phase 3
Completed	`NCT01478789` - Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans	N/A
Completed	`NCT01446679` - Special Drug Use-Results Survey of Lipitor Tablets	N/A
Completed	`NCT01768403` - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia	N/A